Pulmonary hypertension is ameliorated in mice deficient in thrombin-activatable fibrinolysis inhibitor

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 4, 2010, Pages 808-816

  Qin, L ^a   D'Alessandro Gabazza, C N ^a   Aoki, S ^a   Gil Bernabe, P ^a   Yano, Y ^b   Takagi, T ^a   Boveda Ruiz, D ^a   Ramirez Marmol, A Y ^a   San Martin Montenegro, V T ^a   Toda, M ^a   Miyake, Y ^a   Taguchi, O ^a   Takei, Y ^a   Morser, J ^a   Gabazza, E C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Coagulation; Fibrinolysis; Monocrotaline; Vascular remodeling

Indexed keywords

INTERLEUKIN 6; MONOCROTALINE; MONOCYTE CHEMOTACTIC PROTEIN 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL COUNT; CONTROLLED STUDY; ENZYME DEFICIENCY; FIBRINOLYSIS; HEART HYPERTROPHY; LUNG BLOOD VESSEL; LUNG LAVAGE; LYMPHOCYTE COUNT; MACROPHAGE; MALE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY ARTERY; PULMONARY HYPERTENSION; WEIGHT REDUCTION;

ANIMALS; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; CAPILLARY PERMEABILITY; CARBOXYPEPTIDASE U; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; FIBRINOLYSIS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LUNG; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCROTALINE; PLATELET-DERIVED GROWTH FACTOR; PULMONARY ARTERY; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT LOSS;

EID: 77952729147     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03751.x     Document Type: Article

References (32)

1. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004, 351:1655-65. 10.1056/NEJMra035488, 351/16/1655 [pii]; doi
2. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004, 109:159-65. 10.1161/01.CIR.0000102381.57477.50109/2/159, doi, [pii]
3. Welsh CH, Hassell KL, Badesch DB, Kressin DC, Marlar RA. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996, 110:710-7.
4. Hassell KL. Altered hemostasis in pulmonary hypertension. Blood Coagul Fibrinolysis 1998, 9:107-17.
5. Dobrovolsky AB, Titaeva EV. The fibrinolysis system: regulation of activity and physiologic functions of its main components. Biochemistry (Mosc) 2002, 67:99-108. BCM67010116 [pii]
6. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009, 7:4-13. 10.1111/j.1538-7836.2008.03220.x, JTH3220 [pii]; doi
7. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997, 78:386-91.
8. Nagashima M, Yin ZF, Zhao L, White K, Zhu Y, Lasky N, Halks-Miller M, Broze GJ, Fay WP, Morser J. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002, 109:101-10.
9. Nishii Y, Gabazza EC, Fujimoto H, Nakahara H, Takagi T, Bruno N, D'Alessandro-Gabazza CN, Maruyama J, Maruyama K, Hayashi T, Adachi Y, Suzuki K, Taguchi O. Protective role of protein C inhibitor in monocrotaline-induced pulmonary hypertension. J Thromb Haemost 2006, 4:2331-9. 10.1111/j.1538-7836.2006.02174.x, JTH2174 [pii]; doi
10. Yasui H, Gabazza EC, Tamaki S, Kobayashi T, Hataji O, Yuda H, Shimizu S, Suzuki K, Adachi Y, Taguchi O. Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am J Respir Crit Care Med 2001, 163:1660-8.
11. Ikeda Y, Yonemitsu Y, Kataoka C, Kitamoto S, Yamaoka T, Nishida K, Takeshita A, Egashira K, Sueishi K. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 2002, 283. 10.1152/ajpheart.00919.2001, H2021-8; doi
12. Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J 1998, 12:1446-9.
13. Jeffery TK, Wanstall JC. Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 2001, 92:1-20. S0163-7258(01)00157-7 [pii]
14. Tesfamariam B, DeFelice AF. Endothelial injury in the initiation and progression of vascular disorders. Vascul Pharmacol 2007, 46:229-37. 10.1016/j.vph.2006.11.005, S1537-1891(06)00692-6 [pii]; doi
15. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003, 22:358-63.
16. Kofler S, Nickel T, Weis M. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sci (Lond) 2005, 108:205-13. 10.1042/CS20040174, CS20040174 [pii]; doi
17. Strieter RM, Keane MP. Innate immunity dictates cytokine polarization relevant to the development of pulmonary fibrosis. J Clin Invest 2004, 114:165-8. 10.1172/JCI22398, doi
18. Deyo JA, Kerkvliet NI. Tier-2 studies on monocrotaline immunotoxicity in C57BL/6 mice. Toxicology 1991, 70:313-25.
19. Madl AK, Wilson DW, Segall HJ, Pinkerton KE. Alteration in lung particle translocation, macrophage function, and microfilament arrangement in monocrotaline-treated rats. Toxicol Appl Pharmacol 1998, 153:28-38. 10.1006/taap.1998.8515, S0041-008X(98)98515-5 [pii]; doi
20. Hamaguchi M, Morishita Y, Takahashi I, Ogura M, Takamatsu J, Saito H. FDP D-dimer induces the secretion of interleukin-1, urokinase-type plasminogen activator, and plasminogen activator inhibitor-2 in a human promonocytic leukemia cell line. Blood 1991, 77:94-100.
21. Liu X, Piela-Smith TH. Fibrin(ogen)-induced expression of ICAM-1 and chemokines in human synovial fibroblasts. J Immunol 2000, 165:5255-61.
22. Rowland FN, Donovan MJ, Picciano PT, Wilner GD, Kreutzer DL. Fibrin-mediated vascular injury. Identification of fibrin peptides that mediate endothelial cell retraction. Am J Pathol 1984, 117:418-28.
23. Senior RM, Skogen WF, Griffin GL, Wilner GD. Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. J Clin Invest 1986, 77:1014-9. 10.1172/JCI112353, doi
24. Skogen WF, Senior RM, Griffin GL, Wilner GD. Fibrinogen-derived peptide B beta 1-42 is a multidomained neutrophil chemoattractant. Blood 1988, 71:1475-9.
25. Thompson WD, Stirk CM, Melvin WT, Smith EB. Plasmin, fibrin degradation and angiogenesis. Nat Med 1996, 2:493.
26. Leung LL, Myles T, Nishimura T, Song JJ, Robinson WH. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Mol Immunol 2008, 45:4080-3. 10.1016/j.molimm.2008.07.010, S0161-5890(08)00294-0 [pii]; doi
27. Bruno NE, Yano Y, Takei Y, Gabazza EC, Qin L, Nagashima M, Morser J, D'Alessandro-Gabazza CN, Taguchi O, Sumida Y. Protective role of thrombin activatable fibrinolysis inhibitor in obstructive nephropathy-associated tubulointerstitial fibrosis. J Thromb Haemost 2008, 6:139-46. 10.1111/j.1538-7836.2007.02826.x, JTH2826 [pii]; doi
28. Renckens R, Roelofs JJ, ter Horst SA, van't Veer C, Havik SR, Florquin S, Wagenaar GT, Meijers JC, van der Poll T. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol 2005, 175:6764-71. 175/10/6764 [pii]
29. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:13S-24S. 10.1016/j.jacc.2004.02.029, doi, S0735109704004383 [pii]
30. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 2002, 45:173-202. 10.1053/pcad.2002.130041, doi, S0033062002500475 [pii]
31. Arcot SS, Lipke DW, Gillespie MN, Olson JW. Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertension. Biochem Pharmacol 1993, 46:1086-91. 0006-2952(93)90675-M [pii]
32. Barst RJ. PDGF signaling in pulmonary arterial hypertension. J Clin Invest 2005, 115:2691-4. 10.1172/JCI26593, doi